AK112 plus chemo for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (AK112) combined with chemotherapy as a first treatment for advanced esophageal cancer that has spread or cannot be removed. It aims to see if this combination helps shrink tumors and controls the disease longer than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your cancer is advanced (spread or cannot be removed) and has not been treated with any systemic therapy (like chemo or immunotherapy).
- You are able to care for yourself and are up and about at least half the day (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, kidney, and liver function are within normal limits.
- You are not pregnant, breastfeeding, or planning to become pregnant. You agree to use birth control during and for 8 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
This trial tests a new combination of drugs (QL1706, nab-paclitaxel, and cisplatin) as a first treatment for advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if this combination is safe and effective in shrinking tumors and helping patients live longer.
This trial tests adding an immunotherapy drug called adebrelimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination shrinks tumors more and improves outcomes.
This trial tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy for people with advanced esophageal cancer that has not been treated before. The goal is to see if this combination can help shrink tumors and improve outcomes.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.